Loading
A phase 2 trial of Capecitabine, Tislelizumab and Oxaliplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] is a phase 2 interventional study registered as NCT07390383 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-05-30. Interventions recorded: LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection and Oxaliplatin injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nanjing Leads Biolabs, Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Oxaliplatin, Capecitabine and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/